# US 8,784,810 B2 · Treatment of amyloidogenic diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,784,810 B2
- Document ID: US8784810B2
- Status: Granted
- Kind: B2
- Application number: 13/123,898
- Filed: 2008-10-17
- Published: 2011-09-22
- Granted: 2014-07-22
- Earliest claimed: 2006-04-18
- Assignees: Janssen Alzheimer Immunotherapy; Wyeth
- Applicants: Ivan Lieberburg; James Callaway; Michael Grundman
- Inventors: Ivan Lieberburg; James Callaway; Michael Grundman
- Web page: https://patentgrep.com/patent/US8784810B2

## CPC

- C07K 16/18: against material from animals or humans
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61K 2039/505: {comprising antibodies}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention provides preferred dosage ranges, maximum concentrations, average concentrations and monitoring regimes for use in treatment of Alzheimer's disease using antibodies to Aβ. The invention also provides monitoring regimes that as can assess changes in symptoms or signs of the patient following treatment.

## Claims

### Claim 1

A method of treating Alzheimer's disease, comprising:
subcutaneously administering to a patient having the disease an antibody that specifically binds to an N-terminal fragment of Aβ, wherein the antibody is a humanized antibody comprising three light chain CDRs and three heavy chain CDRs of mouse antibody 3D6 expressed by the hybridoma deposited under ATCC under No. PTA-5130, and wherein the antibody is administered at a dosage within a range of 0.05-0.25 mg/kg and a frequency of between weekly and monthly, thereby treating the patient.

### Claim 2 (depends on 1)

The method of claim 1, wherein the humanized-antibody is bapineuzumab.